Clinical Trial Update: Expanded Access Program (EAP) for Tovorafenib (DAY101) in RAF-Altered, Relapsed or Refractory Low-Grade Glioma

View source ↗

Summary

Tovorafenib (DAY101) has been approved for marketing for RAF-altered, relapsed or refractory low-grade glioma, with an Expanded Access Program enabling patient …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Low-grade Glioma

Drugs mentioned

• Tovorafenib (DAY101) (tovorafenib)

Snippet

Sponsor: Day One Biopharmaceuticals, Inc. | Conditions: Low-grade Glioma | Status: APPROVED_FOR_MARKETING